Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

BOSTON & PRINCETON, N.J.--(BUSINESS WIRE)--May 29, 2024--

Related Keywords

Massachusetts ,United States ,Boston ,New Jersey ,Arnold Levine ,Foundationone Cdx ,Kathy Vincent ,Troy Schurr ,Danielle Johns ,Tim Smith ,Pharmaceuticals Inc ,Foundation Medicine Inc ,Greig Communications ,Foundation Medicine ,Linkedin ,Flatiron Health ,Nasdaq ,Drug Administration ,Foundation Medicine Commercial Tissue Or Heme ,Foundation Medicine Clinico ,Head Of Corporate Development ,Chief Biopharma Business Officer ,Fast Track ,Essential Partner ,Rev Drug ,Commercial Tissue ,For Foundation ,Vice President ,Corporate Development ,Business Wire ,